### Measure ID: ASNC19

**Modality**: Nuclear (SPECT, PET)

**Measure Title**: Imaging Protocols for SPECT and PET MPI studies - Use of stress only protocol

**Measure Description**: Percentage of Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) studies where the imaging protocol used was stress only performed on patients 18 years of age or older.

**Numerator**: Number of denominator eligible studies performed where the imaging protocol used was stress only.

**Numerator Exclusions**: None

**Denominator**: All instances of normal stress nuclear Myocardial Perfusion Imaging (MPI) studies performed on patients 18 years of age or older.

**Denominator Exclusions**: None

**High Priority Status**: Yes

**Measure Type**: Outcome

**Inverse Measure**: No

**Number of rates**: 1

**Overall Performance Rate**: N/A

**Measure Rate Type**: Proportional

**Meaningful Measure Area**: Preventable Healthcare Harm

**NQS Domain**: Patient Safety

**NQF ID Number**: N/A

**Risk-Adjusted**: No

---

### Measure ID: ASNC23

**Modality**: Nuclear (SPECT)

**Measure Title**: SPECT-MPI study clinical utilization of Attenuation Correction image acquisition

**Measure Description**: Percentage of Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) studies using Attenuation Correction performed on patients 18 years of age or older.

**Numerator**: Number of denominator eligible studies performed where an Attenuation Correction of CT or Transmission was used or an Attenuation Correction of "Prone" or "Supine" was documented for patients.

**Numerator Exclusions**: None

**Denominator**: Number of SPECT-MPI studies performed on patients 18 years of age or older.

**Denominator Exclusions**: None
## Measure ID
ASNC28

## Modality
Nuclear (SPECT)

## Measure Title
SPECT-MPI effective dose less than or equal to 9 millisieverts as per ASNC guideline recommendations

## Measure Description
Percentage of Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) studies where 9 or less millisieverts of radiation were administered per ASNC guideline recommendations on patients 18 years of age or older.

## Numerator
Number of denominator eligible studies performed where 9 or less millisieverts were administered for the study.

## Denominator
Number of SPECT-MPI studies performed on patients 18 years of age or older.

## High Priority Status
Yes

## Measure Type
Process

## Inverse Measure
No

## Number of rates
1

## Overall Performance Rate
N/A

## Measure Rate Type
Proportional

## Meaningful Measure Area
Patient-Focused Episode of Care

## NQS Domain
Efficiency and Cost Reduction

## NQF ID Number
N/A

## Risk-Adjusted
No

---

## Measure ID
ASNC29

## Modality
Nuclear (SPECT, PET)

## Measure Title
SPECT and PET MPI study documentation of stress perfusion defects

## Measure Description
Percentage of Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) studies where documentation of stress perfusion defects were present.

## Numerator
Number of denominator eligible studies performed where documentation of stress perfusion defects were present.

## Denominator
Number of SPECT-PET MPI studies performed on patients 18 years of age or older.

## High Priority Status
No

## Measure Type
Process

## Inverse Measure
No

## Number of rates
1

## Overall Performance Rate
N/A

## Measure Rate Type
Proportional

## Meaningful Measure Area
Preventable Healthcare Harm

## NQS Domain
Patient Safety

## NQF ID Number
N/A

## Risk-Adjusted
No
Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) studies that were abnormal and contained perfusion defects documentation including location, severity, and size performed on patients 18 years of age or older.

<table>
<thead>
<tr>
<th><strong>Numerator</strong></th>
<th>Number of denominator eligible studies performed where all stress perfusion defects were documented including the defect location, severity, size and type.</th>
</tr>
</thead>
</table>

**Numerator Exclusions**
None

**Denominator**
All instances of stress nuclear Myocardial Perfusion Imaging (MPI) studies that were abnormal performed on patients 18 years of age or older.

**Denominator Exclusions**
None

**Denominator Exceptions**
None

**High Priority Status**
Yes

**Measure Type**
Process

**Inverse Measure**
No

**Number of rates**
1

**Overall Performance Rate**
N/A

**Measure Rate Type**
Proportional

**Meaningful Measure Area**
Transfer of Health Information and Interoperability

**NQS Domain**
Communication and Care Coordination

**NQF ID Number**
N/A

**Risk-Adjusted**
No

---

**Measure ID**
IGR1

**Modality**
Transthoracic Echocardiography

**Measure Title**
Comprehensive TTE studies reporting a measured value of LVEF AND wall motion findings with LVEF < 50%

**Measure Description**
Percentage of comprehensive TTE studies reporting a measured value of LVEF and wall motion findings with LVEF < 50% on patients 18 years of age or older.

**Numerator**
Number of denominator eligible studies reporting a measured value of LVEF by 2D or 3D techniques and wall motion findings in patients with LVEF < 50%.

**Numerator Exclusions**
None

**Denominator**
Comprehensive TTE studies with a LVEF < 50% performed on patients 18 years of age or older.

**Denominator Exclusions**
None

**Denominator Exceptions**
None

**High Priority Status**
Yes

**Measure Type**
Efficiency and Cost/Resource Use

**Inverse Measure**
No

**Number of rates**
1

**Overall Performance Rate**
N/A

**Measure Rate Type**
Proportional

**Meaningful Measure Area**
Appropriate use of Healthcare

**NQS Domain**
Efficiency and Cost Reduction
Measure ID: IGR2  
Modality: Stress Echocardiography  
Measure Title: Parameters in stress echocardiography dobutamine testing for low flow, low gradient aortic stenosis  
Measure Description: Percentage of low flow, low gradient aortic stenosis studies in the setting of LVEF < 50% with complete measurements during a dobutamine stress echocardiogram on patients 18 years of age or older.  
Numerator: Number of denominator eligible studies in which (left ventricular outflow tract diameter (LVOT), LVOT velocity time integral, AND peak aortic valve velocity) OR aortic valve area) AND mean aortic valve gradient AND LVEF are measured at baseline and at peak stage of dobutamine infusion.  
Numerator Exclusions: None  
Denominator: All stress echo studies performed to assess low flow, low gradient aortic stenosis in the setting of LVEF < 50% on patients 18 years of age or older.  
Denominator Exclusions: None  
Inverse Measure: No  
NQF ID Number: N/A  
Risk-Adjusted: No

Measure ID: IGR4  
Modality: Nuclear (SPECT, PET), Stress Echocardiography  
Measure Title: Myocardial Perfusion Imaging (MPI) studies or Stress Echocardiography imaging studies not Equivocal  
Measure Description: Percentage of Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET) or Stress Echocardiography imaging studies that are not equivocal on patients 18 years of age or older.  
Numerator: Number of denominator eligible studies performed where the results were not equivocal.  
Numerator Exclusions: None  
Denominator: All instances of stress nuclear Myocardial Perfusion Imaging (MPI) studies or Stress Echocardiography imaging studies performed on patients 18 years of age or older.  
Denominator Exclusions: None
<table>
<thead>
<tr>
<th>Denominator Exceptions</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>High Priority Status</td>
<td>Yes</td>
</tr>
<tr>
<td>Measure Type</td>
<td>Efficiency and Cost/Resource Use</td>
</tr>
<tr>
<td>Inverse Measure</td>
<td>No</td>
</tr>
<tr>
<td>Number of rates</td>
<td>1</td>
</tr>
<tr>
<td>Overall Performance Rate</td>
<td>N/A</td>
</tr>
<tr>
<td>Measure Rate Type</td>
<td>Proportional</td>
</tr>
<tr>
<td>Meaningful Measure Area</td>
<td>Appropriate use of Healthcare</td>
</tr>
<tr>
<td>NQS Domain</td>
<td>Efficiency and Cost Reduction</td>
</tr>
<tr>
<td>NQF ID Number</td>
<td>N/A</td>
</tr>
<tr>
<td>Risk-Adjusted</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>IGRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modality</td>
<td>Nuclear (SPECT, PET), Transthoracic Echocardiography, Stress Echocardiography</td>
</tr>
<tr>
<td>Measure Title</td>
<td>Myocardial Perfusion Imaging (MPI) studies, Transthoracic Echo (TTE), or Stress Echocardiography imaging studies reporting Left Ventricular Ejection Fraction</td>
</tr>
<tr>
<td>Measure Description</td>
<td>Percentage of Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI), transthoracic echocardiography, or stress echocardiography imaging studies where the Left Ventricle Ejection Fraction (LVEF) was calculated and included in the report performed on patients 18 years of age or older.</td>
</tr>
<tr>
<td>Numerator</td>
<td>Number of denominator eligible studies performed where the Left Ventricular Ejection Fraction was calculated and reported.</td>
</tr>
<tr>
<td>Numerator Exclusions</td>
<td>None</td>
</tr>
<tr>
<td>Denominator</td>
<td>All instances of stress nuclear Myocardial Perfusion Imaging (MPI) studies, Transthoracic Echocardiography (TTE), or Stress Echocardiography imaging studies performed on patients 18 years of age or older.</td>
</tr>
<tr>
<td>Denominator Exclusions</td>
<td>None</td>
</tr>
<tr>
<td>High Priority Status</td>
<td>No</td>
</tr>
<tr>
<td>Measure Type</td>
<td>Process</td>
</tr>
<tr>
<td>Inverse Measure</td>
<td>No</td>
</tr>
<tr>
<td>Number of rates</td>
<td>1</td>
</tr>
<tr>
<td>Overall Performance Rate</td>
<td>N/A</td>
</tr>
<tr>
<td>Measure Rate Type</td>
<td>Proportional</td>
</tr>
<tr>
<td>Meaningful Measure Area</td>
<td>Preventive Care</td>
</tr>
<tr>
<td>NQS Domain</td>
<td>Effective Clinical Care</td>
</tr>
<tr>
<td>NQF ID Number</td>
<td>N/A</td>
</tr>
<tr>
<td>Risk-Adjusted</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>IGR6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modality</td>
<td>Nuclear (SPECT), Stress Echocardiography</td>
</tr>
<tr>
<td>Measure Title</td>
<td>SPECT-MPI or Stress Echocardiography imaging protocol selection for morbidly obese patients</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Measure Description</td>
<td>Percentage of SPECT-MPI or Stress Echocardiography imaging studies where the Imaging Protocol was appropriate for morbidly obese patients on patients 18 years of age or older.</td>
</tr>
<tr>
<td>Numerator</td>
<td>Number of denominator eligible studies performed where the nuclear imaging protocol used was Rest/Stress 2-Day or Stress/Rest 2-day or Stress Echocardiography where contrast was utilized.</td>
</tr>
<tr>
<td>Numerator Exclusions</td>
<td>None</td>
</tr>
<tr>
<td>Denominator</td>
<td>Number of SPECT-MPI or Stress Echocardiography studies performed where the BMI &gt;= 40 on patients 18 years of age or older.</td>
</tr>
<tr>
<td>Denominator Exclusions</td>
<td>None</td>
</tr>
<tr>
<td>High Priority Status</td>
<td>Yes</td>
</tr>
<tr>
<td>Measure Type</td>
<td>Efficiency and Cost/Resource Use</td>
</tr>
<tr>
<td>Inverse Measure</td>
<td>No</td>
</tr>
<tr>
<td>Number of rates</td>
<td>1</td>
</tr>
<tr>
<td>Overall Performance Rate</td>
<td>N/A</td>
</tr>
<tr>
<td>Measure Rate Type</td>
<td>Proportional</td>
</tr>
<tr>
<td>Meaningful Measure Area</td>
<td>Patient-Focused Episode of Care</td>
</tr>
<tr>
<td>NQS Domain</td>
<td>Effective Clinical Care</td>
</tr>
<tr>
<td>NQF ID Number</td>
<td>N/A</td>
</tr>
<tr>
<td>Risk-Adjusted</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Measure Title</th>
<th>IGR7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modality</td>
<td>Nuclear (SPECT), Stress Echocardiography</td>
</tr>
<tr>
<td>Measure Title</td>
<td>SPECT-MPI or Stress Echocardiography imaging studies with adequate exercise testing performed</td>
</tr>
<tr>
<td>Measure Description</td>
<td>Percentage of Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) or Stress Echocardiography exercise studies where the stress heart rate &gt;= 85% of maximum heart rate and three or more minutes of exercise performed on patients 18 years of age or older.</td>
</tr>
<tr>
<td>Numerator</td>
<td>Number of denominator eligible studies performed where the stress heart rate &gt;= 85% of maximum heart rate and three or more minutes of exercise.</td>
</tr>
<tr>
<td>Numerator Exclusions</td>
<td>None</td>
</tr>
<tr>
<td>Denominator</td>
<td>Number of exercise SPECT-MPI or Stress Echocardiography studies performed on patients 18 years of age or older.</td>
</tr>
<tr>
<td>Denominator Exclusions</td>
<td>None</td>
</tr>
<tr>
<td>Denominator Exceptions</td>
<td>None</td>
</tr>
<tr>
<td>High Priority Status</td>
<td>No</td>
</tr>
<tr>
<td>Measure Type</td>
<td>Process</td>
</tr>
<tr>
<td>Inverse Measure</td>
<td>No</td>
</tr>
<tr>
<td>Number of rates</td>
<td>1</td>
</tr>
<tr>
<td>Measure ID</td>
<td>IGR8</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Modality</td>
<td>Nuclear (SPECT), Stress Echocardiography</td>
</tr>
<tr>
<td>Measure Title</td>
<td>SPECT-MPI or Stress Echocardiography study utilization of exercise as a stressor</td>
</tr>
<tr>
<td>Measure Description</td>
<td>Percentage of Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) or Stress Echocardiography studies using a Stress Test Type that includes exercise performed on patients 18 years of age or older.</td>
</tr>
<tr>
<td>Numerator</td>
<td>Number of denominator eligible studies performed where the Stress Test Type includes exercise.</td>
</tr>
<tr>
<td>Numerator Exclusions</td>
<td>None</td>
</tr>
<tr>
<td>Denominator</td>
<td>Number of SPECT-MPI or Stress Echocardiography studies performed on patients 18 years of age or older.</td>
</tr>
<tr>
<td>Denominator Exclusions</td>
<td>Patients with Left Bundle Branch Block (LBBB), a pacemaker or who are unable to exercise.</td>
</tr>
<tr>
<td>Denominator Exceptions</td>
<td>None</td>
</tr>
<tr>
<td>High Priority Status</td>
<td>No</td>
</tr>
<tr>
<td>Measure Type</td>
<td>Process</td>
</tr>
<tr>
<td>Inverse Measure</td>
<td>No</td>
</tr>
<tr>
<td>Number of rates</td>
<td>1</td>
</tr>
<tr>
<td>Overall Performance Rate</td>
<td>N/A</td>
</tr>
<tr>
<td>Measure Rate Type</td>
<td>Proportional</td>
</tr>
<tr>
<td>Meaningful Measure Area</td>
<td>Preventive Care</td>
</tr>
<tr>
<td>NQS Domain</td>
<td>Effective Clinical Care</td>
</tr>
<tr>
<td>NQF ID Number</td>
<td>N/A</td>
</tr>
<tr>
<td>Risk-Adjusted</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>IGR9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modality</td>
<td>Stress Echocardiography</td>
</tr>
<tr>
<td>Measure Title</td>
<td>Stress echo performance for shortness of breath per ASE guidelines</td>
</tr>
<tr>
<td>Measure Description</td>
<td>Stress echo performance for shortness of breath per ASE guidelines on patients 18 years of age or older. This is a multi-strata measure consisting of the following:</td>
</tr>
</tbody>
</table>

1. Percentage of stress echo studies presenting with an indication of unexplained dyspnea that include an interpretation of LV diastolic function parameters with exercise.  
2. Percentage of stress echo studies presenting with significant aortic and mitral valve disease that include reporting of value function and regurgitation with exercise.
The overall performance will be calculated using a weighted average.

**Numerator**

1. Number of denominator eligible studies performed that include interpretation of (LV diastolic function OR estimated LV filling pressures) and estimated pulmonary artery systolic pressure at exercise.
2. Number of denominator eligible studies performed that include reporting of aortic and mitral valve function and regurgitation at exercise.

**Numerator Exclusions**

None

**Denominator**

1. Number of exercise echocardiograms with an indication of unexplained dyspnea performed on patients 18 years of age or older.
2. Number of exercise echocardiograms with an indication known or suspected aortic or mitral regurgitation or being evaluated for valvular heart disease performed on patients 18 years of age or older.

**Denominator Exclusions**

None

**Denominator Exceptions**

None

**High Priority Status**

Yes

**Inverse Measure**

No

**Number of rates**

1

**Overall Performance Rate**

N/A

**Measure Rate Type**

Proportional

**Meaningful Measure Area**

Appropriate use of Healthcare

**NQS Domain**

Effective Clinical Care

**NQF ID Number**

N/A

**Risk-Adjusted**

No

**Measure ID**

IGR10

**Modality**

Transthoracic Echocardiography

**Measure Title**

Transthoracic Echo (TTE) performance per ASE guidelines

**Measure Description**

Transthoracic Echo (TTE) performance per ASE guidelines on patients 18 years of age or older. This is a multi-strata measure consisting of the following:

1. Percentage of comprehensive TTE studies reporting 100% obtainment of required views.
2. Percentage of limited and comprehensive TTE studies where the study quality was poor or technically difficult that utilized contrast.
3. Percentage of comprehensive TTE studies reporting pulmonary artery pressures.
4. Percentage of comprehensive TTE studies reporting diastolic function.
5. Percentage of limited and comprehensive TTE studies reporting cardiac function using strain analysis in patients receiving chemotherapy.

The overall performance will be calculated using a weighted average.

**Numerator**

1. Number of denominator eligible studies utilizing 100% of all required views.
2. Number of denominator eligible studies receiving contrast.
3. Number of denominator eligible studies reporting pulmonary artery pressures.
4. Number of denominator eligible studies documenting LV diastolic function or LV
filling pressure.

5. Number of denominator eligible studies that include strain analysis.

<table>
<thead>
<tr>
<th>Numerator Exclusions</th>
<th>None</th>
</tr>
</thead>
</table>
| Denominator          | 1. Number of comprehensive Transthoracic Echo (TTE) studies performed on patients 18 years of age or older.  
2. Number of limited and comprehensive Transthoracic Echo (TTE) studies where the study quality was poor/technically difficult performed on patients 18 years of age or older.  
3. Number of comprehensive Transthoracic Echo (TTE) studies performed on patients 18 years of age or older.  
4. Number of comprehensive Transthoracic Echo (TTE) studies for heart failure or being evaluated for shortness of breath performed on patients 18 years of age or older.  
5. Number of limited and comprehensive Transthoracic Echo (TTE) studies for indications involving chemotherapy performed on patients 18 years of age or older. |
| Denominator Exclusions | None |
| Denominator Exceptions | None |
| High Priority Status  | Yes |
| Measure Type          | Efficiency and Cost/Resource Use |
| Inverse Measure       | No |
| Number of rates       | 1 |
| Overall Performance Rate | N/A |
| Measure Rate Type     | Proportional |
| Meaningful Measure Area | Appropriate use of Healthcare |
| NQS Domain            | Efficiency and Cost Reduction |
| NQF ID Number         | N/A |
| Risk-Adjusted         | No |

Measure ID: IGR11
Modality: Nuclear (SPECT, PET), Transthoracic Echocardiography, Stress Echocardiography
Measure Title: Myocardial Perfusion Imaging (MPI), Transthoracic Echocardiography (TTE), or Stress Echocardiography studies meeting appropriate use criteria
Measure Description: Percentage of stress echo, TTE, SPECT or PET MPI studies performed that are appropriate on patients 18 years of age or older.
Numerator: Number of denominator eligible studies performed where studies performed were appropriate.
Numerator Exclusions: None
Denominator: All instances of stress nuclear Myocardial Perfusion Imaging (MPI), Transthoracic Echocardiography (TTE) or Stress Echocardiography studies performed on patients 18 years of age or older.
Denominator Exclusions: None
Denominator Exceptions: None
High Priority Status: Yes
Measure Type: Efficiency and Cost/Resource Use
<table>
<thead>
<tr>
<th>Inverse Measure</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of rates</td>
<td>1</td>
</tr>
<tr>
<td>Overall Performance Rate</td>
<td>N/A</td>
</tr>
<tr>
<td>Measure Rate Type</td>
<td>Proportional</td>
</tr>
<tr>
<td>Meaningful Measure Area</td>
<td>Appropriate Use of Healthcare</td>
</tr>
<tr>
<td>NQS Domain</td>
<td>Efficiency and Cost Reduction</td>
</tr>
<tr>
<td>NQF ID Number</td>
<td>N/A</td>
</tr>
<tr>
<td>Risk-Adjusted</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>IGR12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modality</td>
<td>Transthoracic Echocardiography</td>
</tr>
<tr>
<td>Measure Title</td>
<td>Appropriate diagnosis verification and severity grading for valve disease through transthoracic echocardiography (TTE) quantitative parameters.</td>
</tr>
<tr>
<td>Measure Description</td>
<td>This measure addresses changes in cardiac structure and function in patients with aortic stenosis and/or mitral regurgitation. Changes in left ventricular size and function AND quantitative assessment of severity of aortic stenosis and/or mitral regurgitation should be performed in patients with significant left sided valvular lesions. Both sets of data (left ventricle structure and function, and extent of valvular disease) are needed to reach a conclusion about whether valve surgery or repair is needed. While qualitative assessments are commonly employed, they are generally inadequate to determine severity and to track changes over time. This is a multi-strata measure consisting of the following strata:</td>
</tr>
</tbody>
</table>

1. Percentage of transthoracic echocardiogram reports with at least moderate mitral regurgitation including qualitative MR severity, two quantitative MR measurements to support the qualitative severity grading, quantitative LVEF, one quantitative measurement of LV size at end diastole and end systole, AND blood pressure at time of study.  
2. Percentage of transthoracic echocardiogram reports with at least moderate aortic stenosis including peak velocity, mean systolic gradient, aortic valve area, quantitative LVEF, one quantitative measurement of LV size at end diastole and end systole, AND blood pressure at the time of study.  

The overall performance will be calculated using a weighted average. |
| Numerator | 1. Number of transthoracic echocardiogram reports with at least moderate mitral regurgitation including qualitative MR severity, two quantitative MR measurements to support the qualitative severity grading, quantitative LVEF, one quantitative measurement of LV size at end diastole and end systole, AND blood pressure at time of study.  
2. Number of transthoracic echocardiogram reports with at least moderate aortic stenosis including peak velocity, mean systolic gradient, aortic valve area, quantitative LVEF, one quantitative measurement of LV size at end diastole and end systole, AND blood pressure at the time of study. |
| Numerator Exclusions | None |
| Denominator | 1. Number of transthoracic echocardiogram (TTE) studies performed with moderate or greater mitral regurgitation reported on patients 18 years of age or older.  
2. Number of comprehensive transthoracic Echo (TTE) studies performed with moderate or greater aortic valve stenosis reported on patients 18 years of age or |
Measure ID | IGR13
---|---
Modality | Transthoracic Echocardiography
Measure Title | Appropriate Evaluation of Left Ventricular Structure and Systolic Function with Transthoracic Echocardiography (TTE) to Guide Heart Failure and Cardiomyopathy Management
Measure Description | This measure addresses appropriate evaluation of left ventricular structure and systolic function with TTE to guide heart failure and cardiomyopathy management on patients 18 years of age or older. This is a multi-strata measure consisting of the following strata:

1. Percentage (%) of comprehensive transthoracic echocardiogram (TTE) studies performed on patients with heart failure/cardio-myopathy as the reason for the study, and including the following parameters for the study: - LV end-diastolic and end systolic diameters, end diastolic LV interventricular septum thickness and LV posterior wall thickness measurements - LV mass index calculation - Strain technology utilization - Use of intravenous contrast agent to visualize endocardial borders for LV volumes and ejection fraction (EF) measurement in technically difficult studies

2. Percentage (%) of comprehensive TTE studies performed on patients with heart failure/cardio-myopathy as the reason for the study where the LVEF < 40%, that include a recommendation to consider instituting guideline-directed medical therapy for heart failure, including beta-blocker and renin-angiotensin-aldosterone neurohormonal axis blockade and neprilysin/angiotensin receptor inhibitor if clinically indicated.

The overall performance will be calculated using a weighted average.

Numerator

1. Number of denominator eligible studies reporting a quantitative assessment of left ventricular (LV) structure and systolic function including:
- LV end-diastolic and end systolic diameters, end diastolic LV interventricular septum thickness and LV posterior wall thickness measurements
- LV mass index calculation
- Strain technology utilization
- Use of intravenous contrast agent to visualize endocardial borders for LV volumes and ejection fraction (EF) measurement in technically difficult studies
2. Number of denominator eligible studies that include a recommendation to consider...
instituting guideline-directed medical therapy for heart failure, including beta-blocker and renin-angiotensin-aldosterone neurohormonal axis blockade and neprilysn/angiotensin receptor inhibitor if clinically indicated.

**Numerator Exclusions**  
None

**Denominator**  
1. Number of comprehensive TTE studies performed on patients with heart failure/cardiomyopathy as a reason for the study in patients 18 years of age or older.
2. Number of comprehensive TTE studies performed on patients with heart failure/cardiomyopathy as a reason for the study in patients 18 years of age or older where the LVEF < 40%.

**Denominator Exclusions**  
None

**Denominator Exceptions**  
None

**High Priority Status**  
No

**Measure Type**  
Process

**Inverse Measure**  
No

**Number of rates**  
1

**Overall Performance Rate**  
N/A

**Measure Rate Type**  
Proportional

**Meaningful Measure Area**  
Patient-Focused Episode of Care

**NQS Domain**  
Effective Clinical Care

**NQF ID Number**  
N/A

**Risk-Adjusted**  
No

---

**Measure ID**  
322

**Modality**  
Nuclear (SPECT, PET), Stress Echocardiography

**Measure Title**  
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients

**Measure Description**  
Percentage of stress single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), stress echocardiogram (ECHO), cardiac computed tomography angiography (CCTA), or cardiac magnetic resonance (CMR) performed in low-risk surgery patients 18 years or older for preoperative evaluation during the 12-month submission period.

**Numerator**  
Number of stress SPECT MPI, stress echo, CCTA, or CMR primarily performed in low-risk surgery patients for preoperative evaluation within 30 days preceding low-risk non-cardiac surgery.

**Numerator Exclusions**  
None

**Denominator**  
All instances of stress single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), stress echocardiogram (ECHO), cardiac computed tomography angiography (CCTA), or cardiac magnetic resonance (CMR) performed on patients aged 18 years and older during the submission period.

**Denominator Exclusions**  
None

**Denominator Exceptions**  
None

**High Priority Status**  
Yes

**Measure Type**  
Efficiency and Cost/Resource Use

**Inverse Measure**  
Yes
Measure ID: 323
Modality: Nuclear (SPECT, PET), Stress Echocardiography
Measure Title: Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)
Measure Description: Percentage of all stress single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), stress echocardiogram (ECHO), cardiac computed tomography angiography (CCTA), and cardiovascular magnetic resonance (CMR) performed in patients aged 18 years and older routinely after percutaneous coronary intervention (PCI), with reference to timing of test after PCI and symptom status.
Numerator: Number of stress SPECT MPI, stress echo, CCTA and CMR performed in asymptomatic patients within 2 years of the most recent PCI.
Numerator Exclusions: None
Denominator: All instances of stress single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), stress echocardiogram (ECHO), cardiac computed tomography angiography (CCTA), or cardiac magnetic resonance (CMR) performed on patients aged 18 years and older during the submission period.
Denominator Exclusions: None
Denominator Exceptions: None
High Priority Status: Yes
Inverse Measure: Yes
Number of rates: 1
Overall Performance Rate: N/A
Measure Rate Type: Proportional
Meaningful Measure Area: Efficiency and Cost Reduction
NQS Domain: Efficiency and Cost Reduction
NQF ID Number: N/A
Risk-Adjusted: No

Measure ID: 324
Modality: Nuclear (SPECT, PET), Stress Echocardiography
Measure Title: Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients
Measure Description: Percentage of all stress single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), stress echocardiogram (ECHO), cardiac computed tomo...
tomography angiography (CCTA), and cardiovascular magnetic resonance (CMR) performed in asymptomatic, low coronary heart disease (CHD) risk patients 18 years and older for initial detection and risk assessment.

**Numerator**
Number of stress SPECT MPI, stress echo, CCTA, or CMR primarily performed for asymptomatic, low CHD risk patients for initial detection and risk assessment.

**Numerator Exclusions**
None

**Denominator**
All instances of stress single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), stress echocardiogram (ECHO), cardiac computed tomography angiography (CCTA), or cardiac magnetic resonance (CMR) performed on patients aged 18 years and older during the performance period.

**Denominator Exclusions**
None

**Denominator Exceptions**
None

**High Priority Status**
Yes

**Measure Type**
Efficiency and Cost/Resource Use

**Inverse Measure**
Yes

**Number of rates**
1

**Overall Performance Rate**
N/A

**Measure Rate Type**
Proportional

**Meaningful Measure Area**
Efficiency and Cost Reduction

**NQS Domain**
Efficiency and Cost Reduction

**NQF ID Number**
N/A

**Risk-Adjusted**
No